Salva Storie Instagram

What an inspiring few days at #ATS2026! We're leaving feeling incredibly energised by the collective drive to advance respiratory medicine, and the continued focus on what truly matters for patients.

For patients living with respiratory conditions like severe asthma and COPD, there is a clear need for therapies that move beyond symptom relief.

At ATS, we gained invaluable insights reinforcing our commitment to stabilising and stopping disease progression. This work is crucial for preventing devastating patient events like exacerbations and hospitalisations and easing the burden on healthcare systems.

Imagine life with a cough that doesn’t go away and experiencing urinary incontinence, anxiety, depression and social stigma as a result. Refractory chronic cough (RCC) is a debilitating disease that may be associated with hypersensitive nerves. It can cause patients to cough more than 400 times a day and have a substantial impact on physical and psychological health.

Despite its profound impact, there's surprisingly little awareness of this condition, with patients often suffering a burdensome cough for many years, struggling to get a diagnosis or find effective relief.

At #ATS2026, we're committed to changing that by sharing new research on refractory chronic cough to help advance disease management and support patients like Mary Ellen.

For many, uncontrolled severe asthma means a constant battle, with frustrating daily symptoms becoming an accepted norm.

At GSK, we understand how unpredictable exacerbations can profoundly impact social lives, work and mental well-being.

That’s why we’re here at #ATS2026, innovating for the future of respiratory health – so patients like Michael can experience lasting relief, and don’t have to think about their every breath.

What is MAPS technology and how could it help protect against #PneumococcalDisease?

Pneumococcal disease remains a major cause of illness and mortality in infants and adults.

As part of our commitment to these patients, GSK is sharing research at the International Society of Pneumonia and Pneumococcal Diseases (#ISPPD2026) in Copenhagen, highlighting disease burden, epidemiology and vaccine innovation.

Swipe to learn more about MAPS technology.

What is MAPS technology and how could it help protect against #PneumococcalDisease?

Pneumococcal disease remains a major cause of illness and mortality in infants and adults.

As part of our commitment to these patients, GSK is sharing research at the International Society of Pneumonia and Pneumococcal Diseases (#ISPPD2026) in Copenhagen, highlighting disease burden, epidemiology and vaccine innovation.

Swipe to learn more about MAPS technology.

What is MAPS technology and how could it help protect against #PneumococcalDisease?

Pneumococcal disease remains a major cause of illness and mortality in infants and adults.

As part of our commitment to these patients, GSK is sharing research at the International Society of Pneumonia and Pneumococcal Diseases (#ISPPD2026) in Copenhagen, highlighting disease burden, epidemiology and vaccine innovation.

Swipe to learn more about MAPS technology.

What is MAPS technology and how could it help protect against #PneumococcalDisease?

Pneumococcal disease remains a major cause of illness and mortality in infants and adults.

As part of our commitment to these patients, GSK is sharing research at the International Society of Pneumonia and Pneumococcal Diseases (#ISPPD2026) in Copenhagen, highlighting disease burden, epidemiology and vaccine innovation.

Swipe to learn more about MAPS technology.

What is MAPS technology and how could it help protect against #PneumococcalDisease?

Pneumococcal disease remains a major cause of illness and mortality in infants and adults.

As part of our commitment to these patients, GSK is sharing research at the International Society of Pneumonia and Pneumococcal Diseases (#ISPPD2026) in Copenhagen, highlighting disease burden, epidemiology and vaccine innovation.

Swipe to learn more about MAPS technology.

We’re energised to be at #ATS2026 and inspired to push further in our mission to redefine respiratory care for better patient outcomes.

Patients with #asthma and #COPD deserve more than symptom relief. They deserve treatments that protect against exacerbations and prevent lung damage. This week is dedicated to improving outcomes for the millions of people living with chronic respiratory conditions, alongside the healthcare professionals and researchers who make that possible.

A COPD exacerbation, or attack, is more than a bad cough or a few rough days. It's a sudden, serious worsening of symptoms that can cause permanent lung damage and could lead to hospitalisation. This can make everyday tasks like climbing stairs, walking the dog, or carrying groceries harder over time.

But attacks may be preventable. Proactively talking to your healthcare provider about optimising your treatment and other lifestyle changes are some of the most important steps you can take to protect your lungs.

We’re excited to introduce another three of our ten exceptional 2026 GSK IMPACT Award winners that strengthen community resilience and promote health:

@ageuknorwich, supporting older people to stay healthier for longer through health coaching, befriending, clubs, trips and advocacy work.

@empowermentcharity, serving disadvantaged communities in Blackpool and the Fylde Coast, empowering local people to bring about change to their health and wellbeing.

@encompasssouthwest, tackling rural homelessness, poverty and health inequalities in Southwest England through providing trauma informed and person-centred support.

Click the link in our bio to find out more about each inspiring winner. 🧡

At #ATS2026, we're sharing findings from 33 research projects across our portfolio of inhaled therapies and biologics – reflecting our ambitious treatment goals, moving beyond symptom control to transform outcomes for people living with chronic respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD).

Our innovation is driving new treatment approaches including long-acting therapies, which aim to redefine care and alleviate the significant burden on patients and health systems worldwide.

We believe advancing research is one of the most meaningful investments we can make for a healthier future.

We’re excited to introduce the next four of our ten exceptional 2026 GSK IMPACT Award winners that strengthen community resilience and promote health:

@the.greenhousebristol, working to break the silence, stigma and shame of child sexual abuse, and through the power of innovation help families to rebuild their lives after abuse.

@happybabycommunity transforms lives for pregnant women and new mothers who have fled war, trafficking and violence to seek safety for themselves and their babies, by creating a sanctuary across Greater London and the South East where they and their babies can truly thrive.

@therainbowprojectni, an LGBTQIA+ charity changing lives for LGBTQIA+ people and their families in Northern Ireland through tailored health and wellbeing services that mitigate the impact of discrimination, as well as training, campaigning and policy work to eliminate its root causes.

@rasashighland, providing specialist support and advocacy for anyone affected by sexual violence across the Scottish Highlands.

Click the link in our bio to find out more about each inspiring winner. 🧡

We’re excited to introduce three of our ten exceptional 2026 GSK IMPACT Award winners that strengthen community resilience and promote health:

@cansurviveuk, a Manchester-based charity supporting culturally diverse communities living with and beyond cancer.

@colostomyuk, a national charity supporting people living with a stoma through practical help, raising awareness and fighting stigma so no one faces life with a stoma alone.

@createstrengthgroup, supporting people to recover from substance misuse in Bradford, improving health and wellbeing, preventing relapse and developing resilience, life skills and productive pathways that enable individuals to thrive.

Click the link in our bio to find out more about each winner and their inspiring stories. 🧡

Lupus affects nearly 5 million people globally, often leading to significant damage to major organs, including the skin, heart, and inflammation to the kidneys.

For people like Monique who live with lupus, early, targeted intervention can make a positive impact, helping to manage disease progression and reduce the risk of organ damage.

At GSK, we're committed to understanding the immune system's complexities and advancing the science in lupus care to help people like Monique improve their quality of life and thrive.

Join us in making lupus visible today. Wear purple – the awareness colour for lupus – spread the word and hear more from Monique.

#MakeLupusVisible #WorldLupusDay

Meet Simone and Vernelia 🧡

Both ovarian cancer survivors and advocates, they highlight the power of having open conversations with their healthcare team to feel more empowered during their treatment journey.

🎥 Watch to hear more.

#WorldOvarianCancerDay #WOCD2026